Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
The last time groundbreaking data about scib1 was rns’d, the share price miraculously rose the day before. Whilst sclp is a tight ship on information, it appears that once an RNS is being tee’d up it can leak. So on that basis we should see price movement tomorrow.
The presentation sounds promising with new data being published. So why not hang onto BioNTechs coattails? Especially when they are $93 a share.
Why not let some of their gloss rub off on us?
They have an alternative technology but they are aiming for Personalised treatments across 10 candidates.
Will this be the time when the collaboration with BioNTech on chimeric receptors will be reinforced again to show partnership in eliminating this terrible disease?
So yesterday I posted about imminent news and was slated over the use of the word promise and the past failure to meet timescales.
I’m extremely excited to read the RNS which says and I quite;
,we are very pleased to announce that the first patient has been dosed with iSCIB1+ with doublet therapy in line with our previous guidance on timing. As we have previously communicated, we anticipate that iSCIB1+ will be as effective as SCIB1 and could be a promising candidate for registration studies
Ok it was guidance LD mentioned but the important part is that timescales have been met and this in my view is a transformation for the firm.
This I am sure will continue as well as the scib1+ guidance too. This will help raise confidence and along with what’s coming at aacr will lead to a rerating.
Over the years, aacr has meant worldwide publicity of promising treatments so I’m sure that this will result. After all a £30m raise at an SP of 30p is far less dilution so the BOD will be going for that as a funding option.
So do we expect an RNS informing us of recruitment progress or success before Thursday? I’ll leave that answer to yourselves.
However the point still stands. In the past promises have been made which haven’t been kept which you may argue has helped to devalue this share in market capital terms.
One way to improve confidence is to provide regular and successful communications.
Hopefully we’ll get something around AACR.
Yes I’ll be a little more blunt and suggest that given the strengthened team, a demonstration of its effectiveness would be to actually meet a published target for data. What was promised in Q1?
And Thursday is the last day for the markets of Q1.
Hi TF, you are dead right. The team is being broadened out in a planned and concerted manner. They have clear messages to deliver and will receive interest in the new lines too.
Of course Isn’t LD presenting on 8th April too in the USA with a trial update. That’s not going to show a blank particularly as we are recruiting staff with the skills to take us further forward.
Notably we’re also starting to use social media to get the word out too.
Hi RR
The point is that there is a timescale set of buffers which can’t be avoided and will lead to a bid if the loan notes are not paid off. Wether that is on good terms or not is up the BOD, so their skin in the game is handy.
The BOD has to drive the share price up in order to get a fundraise on reasonable terms.
The funds such as Remile etc look for an exit of 20x what they pitched in at so that’s £1 or £1.2bn in real money.
LF wants her £40m for trials on scib1 so this has to be heading for 60p in the summer. They also need to pay off the loan notes by 2025 or RM will have over 30% meaning an offer for the firm.
How old is LD and when will she want to smell the roses?
Like everything sclp it’s slowly coming to a conclusion. Thank goodness!
So is the the first time that they have overtly directed Enquiries to commercial enquiries.? Begs the question is this one of the antibodies with existing interest or not? Given the short notice of the presentation, is this being used to ramp up negotiations?
Again more evidence of an improved commercial negotiation IMHO.
Hi TF,
Trouble is big Pharma has the personalised vaccine results now as opposed to us working up the data. So tomorrow’s conference may be another stone in the wall in building the alternative case. So maybe another RNS tomorrow?
Ho ho ho! Somehow that wasn’t in the JD. So how can you be head of finance without a number 2 who does the numbers and is more of an anorak?
Wheelers and dealers usually aren’t anoraks.
When you have to divide by 1.2 bn you need a large calculator.
So it’s been placed into administration. It’s not a liquidation so there may be a prepack or the components will be sold off. There is a factory plus the IP. Watch this space for redundancy announcements. Given the precarious nature of the finances then these are the options where the vultures can get cheap pickings. Hope we get the forms from the administrators soon.
Really sorry to hear about the King’s cancer. No doubt he’ll get the best of treatment. Of course we don’t know the type yet and no doubt his treatment plan is already settled by his clinicians. The big boys will be banging at the door but I wonder if and what immunotherapy will be advised?
So Seth thinks he can get £6m ish per mab on a non exclusive basis. Someone will have to go much higher for exclusivity but beware the tail which comes alongside. Many firms may notwant to play for the other assets if x is attached.
Chances are there will be a stand off until they also decide to partner on sclp or modi. Then maybe an entire bid.